Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4d99a45cd9d247f0b2e0be29ea4bccc8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.Keywords: advanced colon cancer, angiogenesis, bevacizumab, chemotherapy, metastatic, targeted therapy, vascular endothelial growth factor, gastric cancer, pancreatic cancer, hepatocellular cancer |
|---|